Skip to content
type1.science
Phase 3Active, not recruitingNCT06914895

Tirzepatide phase 3 in T1D with overweight or obesity

Large Lilly phase 3 study testing weekly tirzepatide versus placebo in adults with type 1 diabetes and overweight or obesity, with HbA1c as the primary endpoint.

Primary endpoints

  • Change from baseline in HbA1c

Results so far

No results posted yet.